SMI can inhibit hyperlipid-induced pyroptosis of cardiomyocytes by regulating NLRP3/Caspase1 signaling pathway, thus providing a new way to prevent and treat DCM. This evidence concerns the gene NLRP3 and familial dilated cardiomyopathy.